Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors
Author: Harun M. Patel,Rahul Pawara,Sanjay J. Surana
Publsiher: Elsevier
Total Pages: 208
Release: 2018-11-27
ISBN 10: 0081026625
ISBN 13: 9780081026625
Language: EN, FR, DE, ES & NL

Third Generation EGFR Inhibitors Book Review:

Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends. This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and the possibilities of them overcoming constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors, reviewing both their design strategies and typical anticancer activity

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors
Author: Harun M. Patel,Rahul Pawara,S. J. Surana
Publsiher: Elsevier
Total Pages: 290
Release: 2019-03-15
ISBN 10: 9780081026618
ISBN 13: 0081026617
Language: EN, FR, DE, ES & NL

Third Generation EGFR Inhibitors Book Review:

EGFR inhibitors are useful tools in cancer therapeutics, but resistance to the first generations have significantly increased, meaning a new generation of improved inhibitors are needed with better efficacy and lower toxicity. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. Mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are then explored before a discussion of potential future trends. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems is a guide for medicinal chemists, drug developer, and researchers investigating cancer therapeutics, supporting them in the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and looks at how they may be able to overcome the constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors and reviews both their design strategies and typical anticancer activity

Resistance to Tyrosine Kinase Inhibitors

Resistance to Tyrosine Kinase Inhibitors
Author: Daniele Focosi
Publsiher: Springer
Total Pages: 188
Release: 2016-11-07
ISBN 10: 3319460919
ISBN 13: 9783319460918
Language: EN, FR, DE, ES & NL

Resistance to Tyrosine Kinase Inhibitors Book Review:

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

Central Nervous System Metastases

Central Nervous System Metastases
Author: Manmeet Ahluwalia,Philippe Metellus,Riccardo Soffietti
Publsiher: Springer Nature
Total Pages: 421
Release: 2019-11-05
ISBN 10: 3030234177
ISBN 13: 9783030234171
Language: EN, FR, DE, ES & NL

Central Nervous System Metastases Book Review:

This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors.

Second Line Treatment of Non Small Cell Lung Cancer Clinical Pathological and Molecular Aspects of Novel Promising Drugs

Second Line Treatment of Non Small Cell Lung Cancer  Clinical  Pathological and Molecular Aspects of Novel Promising Drugs
Author: Umberto Malapelle,Pierlorenzo Pallante
Publsiher: Frontiers Media SA
Total Pages: 329
Release: 2017-08-29
ISBN 10: 2889452638
ISBN 13: 9782889452637
Language: EN, FR, DE, ES & NL

Second Line Treatment of Non Small Cell Lung Cancer Clinical Pathological and Molecular Aspects of Novel Promising Drugs Book Review:

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and in the population receiving the maintenance therapy over 16 months. Given these results, more than 60% of patients may receive a second line therapy with further opportunities to improve the length and quality of life. For patients not harbouring targetable DNA mutations newer options will be available for second line therapeutic schemes and two major assets seem to be promising: immune modulation and anti-angiogenetic agents. In particular, anti PD1/PDL1 antibodies, VEGFR antibodies and TKIs, these latter combined with standard chemotherapy docetaxel advance the median overall survival of 12 months. These drugs have a different mechanism of action, various adverse events and their activity is different depending on the types of population. However, the biomarkers’ activity and efficacy prediction are not fully or totally understood. In addition, also for patients with DNA targetable mutations new drugs seems to be promising for the use in the second line therapeutic protocols. In particular, drugs selectively directed against ALK translocation and mutational events and EGFR T790M secondary mutations seems to be very promising. In this Research Topic we critically discuss the older therapies and the historical development of second line, putting in to perspective the new agents available in clinical practice. We discuss their importance from a clinical point of view, but also consider and exploit the complex molecular mechanisms responsible of their efficacy or of the subsequently observed resistance phenomena. In this perspective, the undercovering and characterization of novel predictive biomarkers by NGS technology, the characterization of novel actors in the signal transduction pathway modulating the response of the cells, the optimization of new diagnostic tool as the evaluation of liquid biopsy and the implementation of more suitable pre-clinical models are crucial aspects dissected too. Nivolumab, nintedanib and ramucirumab probably will give the opportunity to improve the efficacy outcomes for the treatment of wild type tumours in second line therapeutic schemes, but many aspects should be debated in order that these agents are made available to patients, planning ahead a therapeutic strategy, beginning from the first line therapy, to the subsequent ones in a logical and affordable manner. As well, for treatment of mutated tumours, mutated EGFR irreversible inhibitors such as rociletinib and AZD9291, and ALK targeting drugs ceritinib and alectinib will also play an important role in the immediate future. Probably the right way is to give all the available opportunities to patients, but challenges and pitfalls should be carefully debated, and by launching this Research Topic we tried to give some practical insights in this changing landscape.

Molecular Mechanisms of Acquired Resistance to Third generation EGFR TKIs in EGFR T790M mutant Lung Cancer

Molecular Mechanisms of Acquired Resistance to Third generation EGFR TKIs in EGFR T790M mutant Lung Cancer
Author: Anonim
Publsiher: Unknown
Total Pages: 329
Release: 2018
ISBN 10:
ISBN 13: OCLC:1051974613
Language: EN, FR, DE, ES & NL

Molecular Mechanisms of Acquired Resistance to Third generation EGFR TKIs in EGFR T790M mutant Lung Cancer Book Review:

Abstract Lung cancer represents the leading cause of cancer-related deaths worldwide. Despite great advances in its management with the recent emergence of molecular targeted therapies for non-small-cell lung cancer (NSCLC), relapse of the metastatic disease always occurs within approximately one year. Epidermal growth factor receptor (EGFR) mutant tumours are the prime example of oncogene addiction and clonal evolution in oncology, regarding the emergence of resistance to first- and second-generation EGFR inhibitors. Multiple studies have revealed that the EGFR-T790M gatekeeper mutation is the main cause of tumour escape. Recently, irreversible pyrimidine-based EGFR inhibitors especially designed for this particular setting have shown robust clinical activity. However, similar to first- and second-generation inhibitors, the development of a diversified set of resistance mechanisms in response to these new compounds is an emerging issue. To date, clinical management of this growing number of patients has not been clearly established, even if anecdotal responses to subsequent molecularly guided therapies have been observed. By exhaustively reviewing and classifying all the preclinical and clinical data published on resistance to third-generation EGFR inhibitors in NSCLC, this work reveals the heterogeneity of the mechanisms that a tumour can develop to evade therapeutic pressure. Strategies currently being tested in clinical trials are discussed in light of these findings.

Colorectal Cancer

Colorectal Cancer
Author: Jindong Chen
Publsiher: BoD – Books on Demand
Total Pages: 128
Release: 2018-05-16
ISBN 10: 1789231000
ISBN 13: 9781789231007
Language: EN, FR, DE, ES & NL

Colorectal Cancer Book Review:

With international experts sharing their experience and knowledge on these different aspects in the management of colorectal cancer, this book has this opportunity to offer all physicians treating colorectal cancer, as well as researchers, updated information concerning the biology, diagnosis, screening, and treatment of colorectal carcinoma. This book provides a detailed evaluation of diagnostic modalities, in-depth analysis of screening for colorectal cancer, recent advances in treatment, and principles and trends in the management of colorectal cancer. This updated knowledge will be an interesting and informative read for any clinician involved in the management of patients with colorectal cancer. In addition, readers such as related physicians, researchers, and colorectal cancer patients are potential beneficiaries of this book.

Targeted Therapies in Lung Cancer Management Strategies for Nurses and Practitioners

Targeted Therapies in Lung Cancer  Management Strategies for Nurses and Practitioners
Author: Marianne Davies,Beth Eaby-Sandy
Publsiher: Springer
Total Pages: 120
Release: 2019-07-16
ISBN 10: 3030165507
ISBN 13: 9783030165505
Language: EN, FR, DE, ES & NL

Targeted Therapies in Lung Cancer Management Strategies for Nurses and Practitioners Book Review:

This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.

Molecular Pathology of Lung Cancer

Molecular Pathology of Lung Cancer
Author: Philip T. Cagle,Timothy Craig Allen,Mary Beth Beasley,Lucian R. Chirieac,Sanja Dacic,Alain C. Borczuk,Keith M. Kerr
Publsiher: Springer Science & Business Media
Total Pages: 216
Release: 2012-06-14
ISBN 10: 1461431972
ISBN 13: 9781461431978
Language: EN, FR, DE, ES & NL

Molecular Pathology of Lung Cancer Book Review:

As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.

Osimertinib and Other Third generation EGFR TKI in EGFR mutant NSCLC Patients

Osimertinib and Other Third generation EGFR TKI in EGFR mutant NSCLC Patients
Author: Anonim
Publsiher: Unknown
Total Pages: 329
Release: 2018
ISBN 10:
ISBN 13: OCLC:1051960790
Language: EN, FR, DE, ES & NL

Osimertinib and Other Third generation EGFR TKI in EGFR mutant NSCLC Patients Book Review:

Abstract Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. Clinical trials have demonstrated the efficacy of osimertinib in this patient population and clinical trials of other third-generation EGFR TKI are currently under way. Additional challenges in this patient population, such as the upfront efficacy of osimertinib, validation of T790M in liquid biopsies as a dynamic predictive marker of efficacy, along with combination with immune checkpoint inhibitors are being explored, representing an extraordinary time of development for EGFR-mutant NSCLC.

Targeted Therapies for Lung Cancer

Targeted Therapies for Lung Cancer
Author: Ravi Salgia
Publsiher: Springer
Total Pages: 238
Release: 2019-06-26
ISBN 10: 3030178323
ISBN 13: 9783030178321
Language: EN, FR, DE, ES & NL

Targeted Therapies for Lung Cancer Book Review:

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

Cancer Evolution

Cancer Evolution
Author: Charles Swanton
Publsiher: Perspectives Cshl
Total Pages: 350
Release: 2017
ISBN 10: 9781621821434
ISBN 13: 1621821439
Language: EN, FR, DE, ES & NL

Cancer Evolution Book Review:

Tumor progression is driven by mutations that confer growth advantages to different subpopulations of cancer cells. As a tumor grows, these subpopulations expand, accumulate new mutations, and are subjected to selective pressures from the environment, including anticancer interventions. This process, termed clonal evolution, can lead to the emergence of therapy-resistant tumors and poses a major challenge for cancer eradication efforts. Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine examines cancer progression as an evolutionary process and explores how this way of looking at cancer may lead to more effective strategies for managing and treating it. The contributors review efforts to characterize the subclonal architecture and dynamics of tumors, understand the roles of chromosomal instability, driver mutations, and mutation order, and determine how cancer cells respond to selective pressures imposed by anticancer agents, immune cells, and other components of the tumor microenvironment. They compare cancer evolution to organismal evolution and describe how ecological theories and mathematical models are being used to understand the complex dynamics between a tumor and its microenvironment during cancer progression. The authors also discuss improved methods to monitor tumor evolution (e.g., liquid biopsies) and the development of more effective strategies for managing and treating cancers (e.g., immunotherapies). This volume will therefore serve as a vital reference for all cancer biologists as well as anyone seeking to improve clinical outcomes for patients with cancer.

Colorectal Cancer

Colorectal Cancer
Author: Luis Rodrigo
Publsiher: BoD – Books on Demand
Total Pages: 440
Release: 2016-09-07
ISBN 10: 9535125443
ISBN 13: 9789535125440
Language: EN, FR, DE, ES & NL

Colorectal Cancer Book Review:

Colorectal cancer (CRC) is a major health problem because it represents around 10% of all cancers and achieves a worldwide estimate of 1.4 million newly diagnosed cases annually, resulting in approximately 700,000 deaths. Approximately 19-31% of patients present liver metastases. At diagnosis, a further 23-38% will develop extra-hepatic disease. Over the past decade, the widespread use of modern chemotherapeutic and biological agents, combined with laparoscopic surgical techniques, has improved the prognosis of metastatic CRC. A better understanding of the biology of the tumor, along with high efficiency of diagnostic and therapeutic methods, as well as the spread of screening programs, will improve the survival of the CRC patients in the near future.

Mitigation of Cancer Therapy Side Effects with Light

Mitigation of Cancer Therapy Side Effects with Light
Author: Raj Nair,René-Jean Bensadoun
Publsiher: Morgan & Claypool Publishers
Total Pages: 47
Release: 2016-11-01
ISBN 10: 1681741393
ISBN 13: 9781681741390
Language: EN, FR, DE, ES & NL

Mitigation of Cancer Therapy Side Effects with Light Book Review:

'Light' from low level laser therapy, through a process called photobiomodulation (PBM), has been in existence in supportive care in cancer, in particular in the management of oral mucositis (OM) in patients undergoing chemotherapy, radiation therapy and haematopoietic stem cell transplantation. In this book the authors attempt to portray the current status of the supportive care interventions that are possible with PBM using low level laser therapy (LLLT) in patients undergoing cancer treatment for solid tumours, harmatological malignancies, and head and neck cancers.

PI3K signalling

PI3K signalling
Author: Klaus Okkenhaug,Martin Turner, Michael R Gold
Publsiher: Frontiers Media SA
Total Pages: 329
Release: 2015-03-05
ISBN 10: 2889194191
ISBN 13: 9782889194193
Language: EN, FR, DE, ES & NL

PI3K signalling Book Review:

The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the role of this pathway in cells of the immune system has been made in recent years, starting with analysis of various PI3K and Pten knockout mice and subsequently mTOR and Foxo knockout mice. Together, these experiments have revealed how PI3Ks control B cell and T cell development, T helper cell differentiation, regulatory T cell development and function, B cell and T cell trafficking, immunoglobulin class switching and much, much more. The PI3Kd inhibitor idelalisib has recently been approved for the treatment of B cell lymphoma. Clinical trials of other PI3K inhibitors in autoimmune and inflammatory diseases are also in progress. This is an opportune time to consider a Research Topic considering when what we have learned about the PI3K signalling module in lymphocyte biology and how this is making an impact on clinical immunology and haematology.

Molecular Targeted Therapy of Lung Cancer

Molecular Targeted Therapy of Lung Cancer
Author: Yuichi Takiguchi
Publsiher: Springer
Total Pages: 327
Release: 2017-01-24
ISBN 10: 9811020027
ISBN 13: 9789811020025
Language: EN, FR, DE, ES & NL

Molecular Targeted Therapy of Lung Cancer Book Review:

This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.

Organofluorine Compounds in Biology and Medicine

Organofluorine Compounds in Biology and Medicine
Author: V Prakash Reddy
Publsiher: Newnes
Total Pages: 330
Release: 2015-01-25
ISBN 10: 044453749X
ISBN 13: 9780444537492
Language: EN, FR, DE, ES & NL

Organofluorine Compounds in Biology and Medicine Book Review:

This book covers topics on biochemically relevant organofluorine compounds and their synthesis and biochemical pathways. Organofluorine compounds have renewed interest in pharmaceutical industry, and therefore a concise book on this topic is highly relevant to the scientific community involved in this area. Covers the synthesis, biochemical, and therapeutic applications of organofluorine compounds Offers a complete text on biochemically relevant organofluorine compounds and their synthesis and mechanistic pathways Provides one of the first major reference books on the biological and medicinal applications of organofluorine chemistry

Lung Cancer and Personalized Medicine

Lung Cancer and Personalized Medicine
Author: Aamir Ahmad,Shirish Gadgeel
Publsiher: Springer
Total Pages: 228
Release: 2015-12-14
ISBN 10: 3319242237
ISBN 13: 9783319242231
Language: EN, FR, DE, ES & NL

Lung Cancer and Personalized Medicine Book Review:

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
Author: Anonim
Publsiher: Academic Press
Total Pages: 292
Release: 2018-11-21
ISBN 10: 0128127384
ISBN 13: 9780128127384
Language: EN, FR, DE, ES & NL

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy Book Review:

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment

Medicinal Chemistry for Practitioners

Medicinal Chemistry for Practitioners
Author: Jie Jack Li
Publsiher: John Wiley & Sons
Total Pages: 416
Release: 2020-06-29
ISBN 10: 1119607302
ISBN 13: 9781119607304
Language: EN, FR, DE, ES & NL

Medicinal Chemistry for Practitioners Book Review:

Presenting both a panoramic introduction to the essential disciplines of drug discovery for novice medicinal chemists as well as a useful reference for veteran drug hunters, this book summarizes the state-of-the-art of medicinal chemistry. It covers key drug targets including enzymes, receptors, and ion channels, and hit and lead discovery. The book hen surveys a drug's pharmacokinetics and toxicity, with a solid chapter covering fundamental bioisosteres as a guide to structure-activity relationship investigations.